Prospective Study into the Incidence of Lambert Eaton Myasthenic Syndrome in Small Cell Lung Cancer

Payne, Miranda; Bradbury, Penny; Lang, Bethan; Vincent, Angela; Han, Cheng; Newsom‐Davis, John; Talbot, Denis

doi:10.1097/jto.0b013e3181c3f4f1

Cited by 53 publications

(39 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Autoimmunity causing increased antibodies against the VGCC P/Q type in SCLC is the cause for LEMS [76,77]. In a prospective study to assess the incidence of clinical and subclinical LEMS in SCLC, 3% of patients had clinical LEMS and 5% were seropositive without clinical manifestation [78 ]. The prevalence of LEMS in SCLC has been estimated at to be 1-1.6% [79,80].…”

Section: Autoimmune Channelopathiesmentioning

confidence: 99%

Lung cancer-induced paraneoplastic syndromes

Yeung

Habra

Thosani

2011

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

show abstract

Section: Autoimmune Channelopathiesmentioning

confidence: 99%

Lung cancer-induced paraneoplastic syndromes

Yeung

Habra

Thosani

2011

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

show abstract

“…4 Three previous studies were designed to establish the prevalence of PNDs in SCLC; one found 2% PND prevalence (3/150) among patients with SCLC from 5 UK centers, 5 but no antibodies were measured. The other 2 studies looked exclusively for Lambert-Eaton myasthenic syndrome (LEMS), finding the prevalence of LEMS in SCLC to be 3% (4/148 6 and 2/63, 7 respectively). Thus the frequency of the entire range of PNDs and neuronal antibodies in SCLC has not been determined systematically.…”

mentioning

confidence: 99%

Paraneoplastic neurologic disorders in small cell lung carcinoma

et al. 2015

Self Cite

View full text Add to dashboard Cite

Objective: To determine the frequency and range of paraneoplastic neurologic disorders (PNDs) and neuronal antibodies in small cell lung carcinoma (SCLC).Methods: Two hundred sixty-four consecutive patients with biopsy-proven SCLC were recruited at the time of tumor diagnosis. All patients underwent full neurologic examination. Serum samples were taken prior to chemotherapy and analyzed for 15 neuronal antibodies. Thirty-eight healthy controls were analyzed in parallel.Results: PNDs were quite prevalent (n 5 24, 9.4%), most frequently Lambert-Eaton myasthenic syndrome (3.8%), sensory neuronopathy (1.9%), and limbic encephalitis (1.5%). Eighty-seven percent of all patients with PNDs had antibodies to SOX2 (62.5%), HuD (41.7%), or P/Q VGCC (50%), irrespective of their syndrome. Other neuronal antibodies were found at lower frequencies (GABAb receptor [12.5%] and N-type VGCC [20.8%]) or very rarely (GAD65, amphiphysin, Ri, CRMP5, Ma2, Yo, VGKC complex, CASPR2, LGI1, and NMDA receptor [all ,5%]). Conclusions:The spectrum of PNDs is broader and the frequency is higher than previously appreciated, and selected antibody tests (SOX2, HuD, VGCC) can help determine the presence of an SCLC. Neurology ® 2015;85:235-239 GLOSSARY HC 5 healthy control; LE 5 limbic encephalitis; LEMS 5 Lambert-Eaton myasthenic syndrome; PCD 5 paraneoplastic cerebellar degeneration; PEM 5 paraneoplastic encephalomyelitis; PND 5 paraneoplastic neurologic disorder; SCLC 5 small cell lung carcinoma; SN 5 sensory neuronopathy.A paraneoplastic neurologic disorder (PND) results from the indirect effect of a tumor on the nervous system or muscle without local invasion or metastasis. PNDs are often associated with antibodies that bind to proteins shared between the tumor and the nervous system.

show abstract

“…Oft kommt es zu autonomen Störungen. Etwa 3 % aller Patienten mit einem SCLC haben klinisch und elektrophysiologisch ein LEMS [ 68 ] und 60 % der Patienten mit einem LEMS haben einen assoziierten Tumor, meist ein SCLC oder Lymphom.…”

Section: Seltenere Paraneoplastische Syndrome Des Zentralen Nervensysunclassified

Neues bei paraneoplastischen Syndromen in der Neurologie

2012

View full text Add to dashboard Cite

Zusammenfassung In nur wenigen Jahren hat sich das Spektrum und damit das Wissen um paraneoplastische Syndrome in der Neurologie deutlich erweitert. Insbesondere hat die Beschreibung neuer fakultativ paraneoplastischer Subgruppen von Enzephalitiden mit gutem Ansprechen auf immunmodulatorische Therapien das klinische und wissenschaftliche Interesse verst?rkt. Das Erkennen dieser Subgruppen mittels neuartiger Autoantik?rper hat unmittelbare therapeutische Konsequenzen. Die fundierte Kenntnis paraneoplastischer Syndrome in der Neurologie ist daher ?u?erst wichtig f?r den Kliniker. Neue wissenschaftliche Erkenntnisse beleuchten interessante Aspekte der Pathophysiologie paraneoplastischer Prozesse, ihrer m?glichen Reversibilit?t und Initiierung. Neue Registerdaten helfen die Epidemiologie paraneoplastischer neurologischer Syndrome besser einzusch?tzen. Der zunehmende Einsatz von ?Biologika? in der Neurologie er?ffnet zuk?nftig neue Therapiechancen. Allerdings f?hrt die mittlerweile entstandene F?lle an neuen Syndromen und Autoantik?rpern auch vielfach zu Verwirrung und Unsicherheit. Diese ?bersichtsarbeit fasst daher neue und wichtige ?ltere Aspekte paraneoplastischer neurologischer Syndrome, ihrer Klassifikation, Pathophysiologie und Behandlung zusammen.

show abstract

Prospective Study into the Incidence of Lambert Eaton Myasthenic Syndrome in Small Cell Lung Cancer

Abstract: Routine measurement of VGCC antibodies in patients without clinical LEMS is unlikely to assist either in management of SCLC or in assessment of prognosis.

Cited by 53 publications

References 21 publications

Lung cancer-induced paraneoplastic syndromes

Lung cancer-induced paraneoplastic syndromes

Paraneoplastic neurologic disorders in small cell lung carcinoma

Neues bei paraneoplastischen Syndromen in der Neurologie

Contact Info

Product

Resources

About